Claims for Patent: 5,714,504
✉ Email this page to a colleague
Summary for Patent: 5,714,504
| Title: | Compositions |
| Abstract: | The novel optically pure compounds Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ and N.sup.+ (R).sub.4 salts of (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole or (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H- benzimidazole, in particular sodium and magnesium salt form thereof, where R is an alkyl with 1-4 carbon atoms, processes for the preparation thereof and pharmaceutical preparations containing the compounds as active ingredients, as well as the use of the compounds in pharmaceutical preparations and intermediates obtained by preparing the compounds. |
| Inventor(s): | Lindberg; Per Lennart (Molndal, SE), Von Unge; Sverker (Fjar.ang.s, SE) |
| Assignee: | Astra Aktiebolag (Sodertalje, SE) |
| Application Number: | 08/376,512 |
| Patent Claims: |
1. A pharmaceutical formulation for oral administration comprising a pure solid state alkaline salt of the (-)-enantiomer of
5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole and a pharmaceutically acceptable carrier.
2. The pharmaceutical formulation according to claim 1 wherein the solid state salt is optically pure. 3. The pharmaceutical formulation according to claim 1, wherein the alkaline salt is a Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ or N.sup.+ (R).sub.4 salt. 4. The pharmaceutical formulation according to claim 1, wherein the solid state salt is in substantially crystalline form. 5. The pharmaceutical formulation according to claim 1 wherein the alkaline salt is a sodium or magnesium salt. 6. A method of inhibiting gastric acid secretion comprising the oral administration of a pharmaceutical formulation comprising a therapeutically effective amount of a pure solid state alkaline salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole and a pharmaceutically acceptable carrier. 7. A method for the treatment of gastrointestinal inflammatory disease comprising the oral administration to a mammal including man in need of such treatment of a pharmaceutical formulation comprising a therapeutically effective amount of a pure solid state alkaline salt of the (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole and a pharmaceutically acceptable carrier. 8. A method for the treatment of gastrointestinal inflammatory diseases comprising the oral administration to a mammal including man in need of such treatment a composition comprising an effective amount of the pure (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole and a pharmaceutically acceptable carrier. 9. A method of inhibiting gastric acid secretion comprising the oral administration of a pharmaceutical composition comprising an effective amount of the pure (-)-enantiomer of 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzi midazole and a pharmaceutically acceptable carrier. 10. The method of claim 6 or 7 wherein the alkaline salt is a Na.sup.+, Mg.sup.2+, Li.sup.+, K.sup.+, Ca.sup.2+ or N.sup.+ (R).sub.4 salt. |
